Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) EBITDA Margin (2021)

Historic EBITDA Margin for Cullinan Therapeutics (CGEM) over the last 1 years, with Q1 2021 value amounting to 7.18%.

  • Cullinan Therapeutics' EBITDA Margin changed N/A to 7.18% in Q1 2021 from the same period last year, while for Dec 2021 it was 360.67%, marking a year-over-year change of. This contributed to the annual value of 360.67% for FY2021, which is N/A changed from last year.
  • According to the latest figures from Q1 2021, Cullinan Therapeutics' EBITDA Margin is 7.18%.
  • Over the past 5 years, Cullinan Therapeutics' EBITDA Margin peaked at 7.18% during Q1 2021, and registered a low of 7.18% during Q1 2021.